David Hutton

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

In this EyePod® episode, David Hutton sits down with Shankar Musunuri, CEO of Ocugen to discuss updated data for OCU400.

The organization is warning the public about the hazards of misusing contact lenses. Contact lens wearers also must take extra care when applying and removing eye cosmetics.

According to the company, the divestment includes Xiidra, on-market treatment for dry eye disease and additional ophthalmic investigational therapies. Novartis will now move forward with a focused portfolio and prioritized therapeutic areas for future growth.

A team of University of Rochester scientists develop computer models of patients’ eyes to identify the ideal IOLs and visual simulators for patients to experience how they will see with them.

According to Outlook, in the FDA’s recently issued CRL it concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.

The specialty pharmaceutical research company’s new retinal vascular dysfunction model can have an impact on the research and development of new drugs for retinal vascular diseases.

Glaucoma specialist Joel Solano, MD, connects patients diagnosed with glaucoma with digital health solutions that can help prevent blindness and vision loss.

Kriya is developing a one-time gene therapy designed to block complement C3 and C5, which are clinically validated substrates targeted by FDA approved therapies, to delay the progression of geographic atrophy.

The Lasker-DeBakey Clinical Medical Research Award, dubbed ‘America’s Nobel,’ recognizes the wide use of optical coherence tomography to manage eye disease, prevent blindness.

The company announced its previously announced agreement to divest its late-stage ophthalmic assets to Laboratoires Théa S.A.S. has been terminated.

Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.

Preservative-free Iyuzeh, launched more than 10 years ago, currently is available in 46 countries, mostly under the brand name Monoprost, with about 1.5 million patients treated monthly, according to the company.

According to a news release, the J-code for SYFOVRE will become effective on October 1, 2023.

The Orbis Flying Eye Hospital will return to Zambia for a 3-week training project in Lusaka coinciding with World Sight Day on October 12.

According to the companies, the partnership will roll out a proprietary system that has earned FDA breakthrough designation, one of the few ophthalmic devices to achieve this status in almost a decade.

To educate patients on the disease, the company has enlisted the help of actor Eric Stonestreet and his mother, Jamey.

Kiora CEO Brian Strem, PhD, offers an update on the development of KIO-301, a molecule that selectively targets retinal ganglion cells, giving them the ability to sense light.

The research will focus on the compound's impact on biomolecular condensates, which are implicated as a key driver of pathology in neurodegeneration and diseases impacting high metabolic organs. Because the retina is one of the highest energy consuming systems in the human body, deficits in energy supply can be catastrophic.

Researchers from the University of Barcelona are looking to unlock the function of genes in order to design therapies to treat patients diagnosed with retinitis pigmentosa.

‘Modern Family’ actor and his mother, Jamey, are sharing their family’s story of GA and AMD to raise awareness of the disease.

Gabriel Diaz has received the Research to Prevent Blindness/Lions Clubs International Foundation Low Vision Research Award.

According to the company, GATHER-2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham.

Earlier this year, the US Centers for Disease Control and Prevention issued an advisory, sounding the alarm for an outbreak of a drug resistant strain of the bacteria Pseudomonas aeruginosa that was connected to the use of artificial tears.

The company has released a video presentation that highlights combining genetic markers with high-resolution retinal imaging to assist in the detection and treatment of blindness and multiple systemic diseases.

Few treatment options available for early stages of disease.

Research from Orbis International analyzes the overall wellbeing of children with common childhood vision problems.

According to a study, optical coherence tomography-based elastography holds promise for research and diagnosis of ocular diseases.

A Knox County Circuit Court jury awarded Gerald McCoy $6 million and his wife Deborah McCoy should $1 million after March 2017 procedure resulted in the loss of his eye.

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.